The Technical Analyst
Vaxxinity, Inc. [VAXX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vaxxinity, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.43% $0.476
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 60.34 mill |
| EPS: | -0.450 |
| P/E: | -1.060 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 126.75 mill |
| Avg Daily Volume: | 0.443 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.060 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.18x |
| Company: PE -1.060 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0801 (-116.82%) $-0.556 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.402 - 0.550 ( +/- 15.54%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-03 | Paula Molina Rene | Buy | 0 | |
| 2023-10-02 | Powchik Peter | Buy | 159 744 | Stock option (right to buy) |
| 2023-10-01 | Ray Sumita | Buy | 0 | |
| 2023-09-06 | Prime Movers Lab Fund I Lp | Sell | 5 308 | Class A Common Stock |
| 2023-09-07 | Prime Movers Lab Fund I Lp | Sell | 20 312 | Class A Common Stock |
| INSIDER POWER |
|---|
| 49.34 |
| Last 91 transactions |
| Buy: 5 925 518 | Sell: 2 685 509 |
Forecast:
16:00 - $0.463
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.463
Forecast 2: 16:00 - $0.463
Forecast 3: 16:00 - $0.463
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.476 (2.43% ) |
| Volume | 0.282 mill |
| Avg. Vol. | 0.443 mill |
| % of Avg. Vol | 63.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VAXX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VAXX
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
Latest Press Releases
2024-04-19 18:53:00 - Press Release
Vaxxinity Issues Shareholder Letter
Cape canaveral, fla., april 19, 2024 (globe newswire) -- vaxxinity, inc. (“vaxxinity”, “we”, “us” or the “company”) (nasdaq: vaxx), a u.s. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its co-founder and executive chairman, lou reese and chief executive officer, mei mei hu.
2024-04-19 16:27:00 - Press Release
Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Cape canaveral, fla., april 19, 2024 (globe newswire) -- vaxxinity, inc. (“vaxxinity”, “we”, “us” or the “company”) (nasdaq: vaxx), a u.s. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the nasdaq global market (“nasdaq”) and to deregister its class a common stock under section 12(b) and section 12(g) of the securities exchange act of 1934, as amended (the “exchange act”), and suspend its reporting obligations under section 15(d) of the exchange act.
2024-03-28 09:23:00 - Press Release
Vaxxinity To Present Clinical Data At The Annual Academy Of Neurology 2024 Annual Meeting
Presentation will address the company's clinical data in parkinson's disease presentation will address the company's clinical data in parkinson's disease
2024-03-27 16:41:00 - Press Release
Vaxxinity Reports Fourth Quarter And Full-year 2023 Financial Results And Provides Corporate Updates
Cape canaveral, fla., march 27, 2024 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
2024-03-07 10:32:00 - Press Release
Vaxxinity Announces Positive Target Engagement Data From Phase 1 Clinical Trial For Parkinson's Disease At Ad/pd™ 2024
Ub-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of parkinson's patients ub-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of parkinson's patients
Latest News
2024-03-28 09:23:00 - GlobeNewsWire
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease
2024-02-13 08:00:00 - GlobeNewsWire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease and preclinical data from its anti-tau program in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal.
2023-12-11 10:32:49 - Zacks Investment Research
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
2023-11-13 18:50:00 - GlobeNewsWire
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November.
2023-09-07 11:17:27 - Zacks Investment Research
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)
The heavy selling pressure might have exhausted for Vaxxinity, Inc. (VAXX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-08-29 08:00:00 - GlobeNewsWire
Vaxxinity to Present at Upcoming Investor Conferences in September
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in New York in September:
2023-03-28 08:00:00 - GlobeNewsWire
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress
2023-03-02 08:00:00 - GlobeNewsWire
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference
2023-02-13 22:51:32 - 24/7 Wall Street
The 5 Best and Worst Performing Small-Cap Stocks in January 2023
Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market.
2023-01-19 14:04:28 - The Motley Fool
Why Shares of Vaxxinity Jumped This Week
Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.